Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses.

Betts BC, St Angelo ET, Kennedy M, Young JW.

Blood. 2011 Nov 10;118(19):5340-3. doi: 10.1182/blood-2011-06-363390. Epub 2011 Sep 22.

2.

Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480.

Xin H, Herrmann A, Reckamp K, Zhang W, Pal S, Hedvat M, Zhang C, Liang W, Scuto A, Weng S, Morosini D, Cao ZA, Zinda M, Figlin R, Huszar D, Jove R, Yu H.

Cancer Res. 2011 Nov 1;71(21):6601-10. doi: 10.1158/0008-5472.CAN-11-1217. Epub 2011 Sep 15.

3.

Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen.

Betts BC, Abdel-Wahab O, Curran SA, St Angelo ET, Koppikar P, Heller G, Levine RL, Young JW.

Blood. 2011 Nov 10;118(19):5330-9. doi: 10.1182/blood-2011-06-363408. Epub 2011 Sep 13.

4.

Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis.

Liu L, Okada S, Kong XF, Kreins AY, Cypowyj S, Abhyankar A, Toubiana J, Itan Y, Audry M, Nitschke P, Masson C, Toth B, Flatot J, Migaud M, Chrabieh M, Kochetkov T, Bolze A, Borghesi A, Toulon A, Hiller J, Eyerich S, Eyerich K, Gulácsy V, Chernyshova L, Chernyshov V, Bondarenko A, Grimaldo RM, Blancas-Galicia L, Beas IM, Roesler J, Magdorf K, Engelhard D, Thumerelle C, Burgel PR, Hoernes M, Drexel B, Seger R, Kusuma T, Jansson AF, Sawalle-Belohradsky J, Belohradsky B, Jouanguy E, Bustamante J, Bué M, Karin N, Wildbaum G, Bodemer C, Lortholary O, Fischer A, Blanche S, Al-Muhsen S, Reichenbach J, Kobayashi M, Rosales FE, Lozano CT, Kilic SS, Oleastro M, Etzioni A, Traidl-Hoffmann C, Renner ED, Abel L, Picard C, Maródi L, Boisson-Dupuis S, Puel A, Casanova JL.

J Exp Med. 2011 Aug 1;208(8):1635-48. doi: 10.1084/jem.20110958. Epub 2011 Jul 4.

5.

A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation.

Nelson EA, Sharma SV, Settleman J, Frank DA.

Oncotarget. 2011 Jun;2(6):518-24. Review.

6.

The JAK2 exon 12 mutations: a comprehensive review.

Scott LM.

Am J Hematol. 2011 Aug;86(8):668-76. doi: 10.1002/ajh.22063. Epub 2011 Jun 14. Review.

7.

Absence of Stat1 in donor CD4⁺ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice.

Ma H, Lu C, Ziegler J, Liu A, Sepulveda A, Okada H, Lentzsch S, Mapara MY.

J Clin Invest. 2011 Jul;121(7):2554-69. doi: 10.1172/JCI43706. Epub 2011 Jun 13.

8.

The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.

Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R, Wu Z, Gönen M, Mulvey LA, Bessarabova MO, Huh SJ, Silver SJ, Kim SY, Park SY, Lee HE, Anderson KS, Richardson AL, Nikolskaya T, Nikolsky Y, Liu XS, Root DE, Hahn WC, Frank DA, Polyak K.

J Clin Invest. 2011 Jul;121(7):2723-35. doi: 10.1172/JCI44745.

9.

STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis.

Corcoran RB, Contino G, Deshpande V, Tzatsos A, Conrad C, Benes CH, Levy DE, Settleman J, Engelman JA, Bardeesy N.

Cancer Res. 2011 Jul 15;71(14):5020-9. doi: 10.1158/0008-5472.CAN-11-0908. Epub 2011 May 17.

10.

A distal enhancer in Il12b is the target of transcriptional repression by the STAT3 pathway and requires the basic leucine zipper (B-ZIP) protein NFIL3.

Smith AM, Qualls JE, O'Brien K, Balouzian L, Johnson PF, Schultz-Cherry S, Smale ST, Murray PJ.

J Biol Chem. 2011 Jul 1;286(26):23582-90. doi: 10.1074/jbc.M111.249235. Epub 2011 May 12.

11.

Stat3-driven cancer-related inflammation as a key therapeutic target for cancer immunotherapy.

Kato T.

Immunotherapy. 2011 May;3(5):587-90. doi: 10.2217/imt.11.26. No abstract available.

12.

Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation.

Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, Jack RS, Wunderlich FT, Brüning JC, Müller W, Rudensky AY.

Immunity. 2011 Apr 22;34(4):566-78. doi: 10.1016/j.immuni.2011.03.018.

13.

Th17 cells express interleukin-10 receptor and are controlled by Foxp3⁻ and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner.

Huber S, Gagliani N, Esplugues E, O'Connor W Jr, Huber FJ, Chaudhry A, Kamanaka M, Kobayashi Y, Booth CJ, Rudensky AY, Roncarolo MG, Battaglia M, Flavell RA.

Immunity. 2011 Apr 22;34(4):554-65. doi: 10.1016/j.immuni.2011.01.020.

14.

At 17, in-10's passion need not inflame.

Stewart CA, Trinchieri G.

Immunity. 2011 Apr 22;34(4):460-2. doi: 10.1016/j.immuni.2011.04.004.

15.

Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer.

Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Klöppel G, Yoshimura A, Reindl W, Sipos B, Akira S, Schmid RM, Algül H.

Cancer Cell. 2011 Apr 12;19(4):456-69. doi: 10.1016/j.ccr.2011.03.009.

16.

Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression.

Fukuda A, Wang SC, Morris JP 4th, Folias AE, Liou A, Kim GE, Akira S, Boucher KM, Firpo MA, Mulvihill SJ, Hebrok M.

Cancer Cell. 2011 Apr 12;19(4):441-55. doi: 10.1016/j.ccr.2011.03.002.

17.

The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment.

Li N, Grivennikov SI, Karin M.

Cancer Cell. 2011 Apr 12;19(4):429-31. doi: 10.1016/j.ccr.2011.03.018.

18.

Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor.

Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB, Tweardy DJ.

Blood. 2011 May 26;117(21):5701-9. doi: 10.1182/blood-2010-04-280123. Epub 2011 Mar 29.

19.

Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells.

Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, Malchinkhuu E, Wersto RP, Biragyn A.

Cancer Res. 2011 May 15;71(10):3505-15. doi: 10.1158/0008-5472.CAN-10-4316. Epub 2011 Mar 28.

20.

Both miR-17-5p and miR-20a alleviate suppressive potential of myeloid-derived suppressor cells by modulating STAT3 expression.

Zhang M, Liu Q, Mi S, Liang X, Zhang Z, Su X, Liu J, Chen Y, Wang M, Zhang Y, Guo F, Zhang Z, Yang R.

J Immunol. 2011 Apr 15;186(8):4716-24. doi: 10.4049/jimmunol.1002989. Epub 2011 Mar 7.

Supplemental Content

Support Center